News

Los Angeles, California – June 22, 2015.    Vault Pharma (VPI) (www.vaulpharma.com), a biotechnology company developing immune therapies for cancer and infectious diseases, announced the addition of two high profile immune oncology experts to its Scientific Advisory Board. James Mulé Ph.D. and Antoni Ribas M.D. Ph.D. will join scientific founder Leonard Rome Ph.D. and Paul Wender Ph.D. in advising the company on research and development efforts. “This is a tremendous step for VPI,” said Michael…

Los Angeles, California – February 6, 2015.    Vault Pharma announced that it has been granted a U.S. patent titled Vault Complexes for Cytokine Delivery. This patent supports Vault Pharma’s ImmunOncologyTM portfolio, a group of new medicines activating specific responses of the immune system to destroy cancer. Vault Pharma’s lead cancer drug, VPI-101, is a cytokine-based immune stimulant that is delivered by a novel human protein nanoparticle, called a vault. VPI-101 is on schedule to…

Los Angeles, California – January 19, 2015.    Vault Pharma announced that its clinical manufacturing collaboration with Protein Sciences Corporation has been initiated to produce its lead immunotherapeutic against lung cancer. The collaboration is for the production of Vault Pharma’s lead cancer drug, VPI-101. VPI-101 is a cytokine-based immune stimulant that is delivered by a novel human protein nanoparticle, called a vault. Discovered at UCLA, vaults are being commercialized for a number of therapeutic indications…